WASHINGTON, D.C. (Thursday, June 23, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage of The Leahy-Smith America Invents Act, H.R. 1249, by the House of Representatives:
"Small biotechnology companies rely heavily on their patents to attract investment to fund the lengthy and expensive research and development process necessary to bring breakthrough medical therapies and other products to patients and consumers. Strong intellectual property protection is critical for these companies.
"The Leahy-Smith America Invents Act will bring our patent system into the 21st century. The improvements made by the bill will benefit all sectors of the national economy by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system.
"BIO commends Judiciary Committee Chairman Lamar Smith (R-TX) for shepherding The Leahy-Smith America Invents Act through the House. By modernizing and strengthening America's patent system, this legislation will continue our nation's global leadership in innovation while driving job growth throughout our economy.
"BIO will continue to work with House and Senate leaders to ensure that final patent reform legislation addresses any remaining concerns and is enacted into law this year." Upcoming BIO Events
Partnering for Global Health Forum 2011
June 27, 2011
BIO International Convention
June 27-30, 2011
2011 BIO Human Resources Conference
June 26-28, 2011
The Business Forum at the BIO International Convention
June 28-30, 2011
BIO India International Partnering Conference
September 21-22, 2011
BIO China International Conference
October 12-13, 2011